Life Science Investing GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
Life Science Investing GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates
Life Science Investing GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress